Vilanterol - NDSRI's
References
FAQ's
References
- Box, Philip Charles; Coe, Diane Mary; Looker, Brian Edgar; Procopiou, Panayiotis Alexandrou, “Phenethanolamine Derivatives For Treatment Of Respiratory Diseases”, Glaxo Group Limited, United Kingdom, EP1425001B1, September 11, 2002.
- Goergens, Christian; Guddat, Sven; Thomas, Andreas; Wachsmuth, Philipp; Orlovius, Anne-Katrin; Sigmund, Gerd; Thevis, Mario; Schaenzer, Wilhelm, “Simplifying and expanding analytical capabilities for various classes of doping agents by means of direct urine injection high performance liquid chromatography high resolution/high accuracy mass spectrometry”, Journal of Pharmaceutical and Biomedical Analysis, Volume: 131, Pages: 482-496, 2016
Frequently Asked Questions
How are Vilanterol impurities identified?
Vilanterol impurities can be identified using various analytical techniques such as High-Performance Liquid Chromatography (HPLC), liquid chromatography mass spectrometry (LC-MS), etc.
How are impurities removed from Vilanterol?
Vilanterol impurities can be removed from the drug using various techniques such as chromatography, recrystallization, and solvent extraction.
What chromatography techniques are used in the purification of Vilanterol impurities?
Preparative HPLC, Flash Chromatography, and TLC are chromatographic techniques used for the purification of Vilanterol impurities. These techniques separate the impurities from Vilanterol and help in the drug’s purification.
What are the temperature conditions required to store Vilanterol impurities?
Vilanterol impurities should be stored at a controlled room temperature of between 2-8 ⁰C.
Note: Products protected by valid patents by a manufacturer are not offered for sale in countries having patent protection. The sale of such products constitutes a patent infringement, and its liability is at the buyer's risk.